Skip to main content Skip to search Skip to main navigation
High-quality products
Customized solutions
Personal contact
Fast service
Competent technical support +49(0)731-3608-123

3x FLAG Peptide - DYKDDDDK-DYKDDDDK-MDYKDDDDK

Mehr Lesen

Product information "3x FLAG Peptide - DYKDDDDK-DYKDDDDK-MDYKDDDDK"

The DYKDDDDK peptide was developed specifically for immunoaffinity chromatography. The peptide allows the competitive elution of proteins (amino terminal, metaminoterminal or carboxy-terminal) FLAG® fusion proteins from anti-FLAG M1 or anti-FLAG M2 antibodies (in solution or bound and agarose) under mild, non-denaturing conditions.

Application
Usual working concentration is 100µg/mL.
For stock solution, dissolve in TBS (10mM Tris/HCl, 150mM NaCl, pH7.4) to a final concentration of 5mg/mL.

FLAG®: FLAG is a registered trademark of Sigma-Aldrich Co. LLC

Specifications:
Purity: >95% (HPLC)
Sequence: DYKDDDDK-DYKDDDDK-DYKDDDDK
Sequence (3 letter code): Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys
Formula: C123H176N30O58
MW: 3002.91 g/mol
Lyophilized white powder

Source:

synthetic

Classification:

eclass no.: 32-16-04-09
Documents - Protocols - Downloads :
Here you will find information and further literature. For further documents (certificates with additional lot numbers, safety data sheets in other languages, further product information) please contact Genaxxon biosience at: info@genaxxon.com or phone: +49 731 3608 123.


Documents:

Certificate
General Data 1
Skip product gallery

Accessory Items

MOG (92-106) DEGGYTCFFRDHSYQ

MOG (92-106) DEGGYTCFFRDHSYQ represents a short peptide sequence of the protein lipid part of the myelin sheath. Such proteins are obviously targets of the immune defense in multiple sclerosis. Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), is characterised by primary demyelination. It is widely thought that this is the result of an autoimmune attack against myelin components. Potential target antigens in MS are proteins of the myelin sheath such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP). Experimental autoimmune encephalomyelitis (EAE) has proven to be a particularly useful animal model. T cell epitopes of MOG for the induction of EAE in mice have been identified. Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.

Regular price: From €166.66
MOG (183-191) FVIVPVLGP

MOG (183-191) FVIVPVLGP represents a short peptide sequence of the protein lipid part of the myelin sheath. Such proteins are obviously targets of the immune defense in multiple sclerosis. Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), is characterised by primary demyelination. It is widely thought that this is the result of an autoimmune attack against myelin components. Potential target antigens in MS are proteins of the myelin sheath such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP). Experimental autoimmune encephalomyelitis (EAE) has proven to be a particularly useful animal model. T cell epitopes of MOG for the induction of EAE in mice have been identified. Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.

Regular price: From €126.75
MOG (35-55) Ratte/Maus MEVGWYRSPFSRVVHLYRNGK

The MOG peptide fragment 35-55 (Myelin Oligodendrocyte Glycoprotein Peptide Fragment 35-55) induces experimental autoimmune encephalomyelitis in rodents. A single injection of this peptide produces a relapsing-remitting neurologic disease (multiple sclerosis, MS) with extensive plaque-like demyelination. Other experiments show that immunization with MOG (35-55) suppresses spontaneous regeneration of dopaminergic neurons injured with MPTP (a neurotoxin) >. Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), is characterised by primary demyelination. It is widely thought that this is the result of an autoimmune attack against myelin components. Potential target antigens in MS are proteins of the myelin sheath > such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein ( MBP, 1-11 human: P2271 > 54-72 human: P2272 >), and proteolipid protein PLP, 139-151: P2273 > 178-191: P2274 >). Experimental autoimmune encephalomyelitis (EAE) has proven to be a particularly useful animal model for MS. T cell epitopes of MOG for the induction of EAE in mice have been identified. Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches.An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.

Regular price: From €166.66
MOG (97-108) TCFFRDHSYQEE

MOG (97-108) TCFFRDHSYQEE represents a short peptide sequence of the protein lipid part of the myelin sheath. Such proteins are obviously targets of the immune defense in multiple sclerosis. Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), is characterised by primary demyelination. It is widely thought that this is the result of an autoimmune attack against myelin components. Potential target antigens in MS are proteins of the myelin sheath such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP). Experimental autoimmune encephalomyelitis (EAE) has proven to be a particularly useful animal model. T cell epitopes of MOG for the induction of EAE in mice have been identified. Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.

Regular price: From €166.66
MOG (91-108), rat SDEGGYTCFFRDHSYQEE

MOG (91-108) SDEGGYTCFFRDHSYQEE represents a short peptide sequence of the protein lipid part of the myelin sheath. Such proteins are obviously targets of the immune defense in multiple sclerosis. Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS), is characterised by primary demyelination. It is widely thought that this is the result of an autoimmune attack against myelin components. Potential target antigens in MS are proteins of the myelin sheath such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid protein (PLP). Experimental autoimmune encephalomyelitis (EAE) has proven to be a particularly useful animal model. T cell epitopes of MOG for the induction of EAE in mice have been identified. Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007) ChemMedChem 2, 1674-1692.

Regular price: From €245.02